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ABSTRACT
Traumatic brain injuries (TBIs) are a type of acquired head trauma that results from an
external force to the head. The development and severity of the secondary injury increases the
risk of neurodegeneration and reduced cognitive recovery. Glucocorticoids are potent antiinflammatory therapeutics that have been investigated for potential treatment of TBIs, strokes,
and other neuroinflammatory pathologies. However, their clinical application has been limited
due to their ability to induce a variety of side effects, including adrenal suppression, edema, and
reduced plasticity of the hippocampus. The use of a localized drug delivery system would
overcome these systemic concerns. In previous studies, semi-interpenetrating networks (semiIPNs) incorporating dexamethasone-conjugated hyaluronic acid (HA-DXM) as a
macromolecular prodrug were developed. These semi-IPNs reduced neuroinflammation and
improved motor function when applied to the cortical surface following a TBI. A subtype of
TBIs are penetrating brain injuries (PBIs), which occur when a foreign object, such as a bullet,
strikes the cranial cavity creating an opened wound. Due to the irregular geometry of PBIs, there
is a need for hydrogels to be fabricated in an injectable, or dispersible, microparticulate form.
The previous studies utilized a photo-initiated, radical polymerization crosslinking method that
was found not to be effective or scalable in this form. Therefore, the objective of this work was
to develop a new hydrogel formulation compatible with fabrication of microgels. Thiolated
gelatin (gelatin-SH) and poly(ethylene glycol) diacrylate (PEGdA) were synthesized,
characterized, and then successfully crosslinked utilizing a Michael-type reaction to form
hydrogels. Additionally, native hyaluronic acid (HA) was incorporated to model HA-based
macromolecular prodrugs, such as HA-DXM. The effects of gelatin-SH concentration and HA
(700 kDA and 1.5 MDa) on crosslinking time, storage modulus, swelling, and degradation were

2

investigated using bulk hydrogel samples. Both the addition of HA and increasing gelatin-SH
concentrations produced an increased hydrogel storage modulus. Hydrogel microparticles were
then fabricated in a water-in-oil emulsion system, producing particles with an average diameter
ranging from approximately 125 to 250 microns depending on composition and stir rate. These
studies demonstrate that gelatin-SH/PEGdA can create microparticles capable of conforming to
the irregular geometry of PBIs. Future work will focus on the incorporation of HA-DXM into the
hydrogel microparticles and the evaluation of drug-release and therapeutic efficacy in an animal
PBI model.
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1. BACKGROUND
1.1 The Brain – Anatomy & Physiology:
The main command center of the human body is the nervous system. There are two
divisions: the peripheral nervous system (PNS) and the central nervous system (CNS) (Figure
1.1). The CNS includes the brain and spinal cord, while the PNS is most easily described as the
nerves outside of the CNS [1]. The PNS includes the somatic and autonomic nervous systems.
The somatic nervous system controls voluntary movement by the skeletal muscles. The
autonomic nervous system directs involuntary physiologic processes [8]. It can further be
separated into the sympathetic and parasympathetic divisions, which regulate ‘fight or flight’ and
‘rest and digest’ respectively [3].

Figure 1.1: Divisions of the nervous system [1]
The brain is found in the cranial cavity and consists of three divisions: hindbrain,
midbrain, and forebrain [9] (Figure 1.2). The hindbrain is the most primitive part of the brain and
controls the most unconscious functions needed for survival as well as basic movement [10].
This portion of the brain consists of the cerebellum, pons, and medulla oblongata. The
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cerebellum is responsible for most movement, while the pons act as a connector between the
cerebellum and forebrain [11]. The medulla oblongata regulates functions of the cardiovascular
system such as breathing, blood pressure, and heart rate [3]. The midbrain controls most senses,
such as hearing, vision, temperature, and arousal [12]. It is separated into the tectum and
tegmentum. The tectum is composed of four colliculi separated into two pairs known as the
inferior and superior colliculus [9]. The inferior colliculus is a component of the auditory
pathway. The superior colliculus helps process awareness about one’s environment through
vision, hearing, and touch [1]. The tegmentum utilizes the cranial nerves to send and receive
information [13].

Figure 1.2: The divisions of the brain [2]
The forebrain, which is the largest portion of the brain, oversees more complex functions
that are not associated with basic survival [13]. These functions include learning, emotions,
coordination, and problem-solving [10]. The cerebral cortex, limbic system, cerebellum, and
pituitary gland make up this portion of the brain [12]. The cerebral cortex consists of the cerebral
hemisphere, which can further be broken down in the four lobes of the brain (Figure 1.3). The
frontal lobe is primarily concerned with motor functions, such as voluntary movement and
speech production, with the precentral gyrus being the primary motor cortex [9]. The temporal
lobe is responsible for auditory processing, as well as memory [1]. The occipital lobe deals with
10

visual perception. The parietal lobe is mainly associated with somatosensation, with the
postcentral gyrus being its primary cortex [13]. The limbic system is a region of the cerebral
cortex that is comprised of the structures involved in memory, emotion, and complex behavior
[9]. It is primarily composed of five structures: the basal ganglia, the hypothalamus, the
amygdala, the thalamus, and the hippocampus [11]. The hippocampus forms long-term memories
[10]. The amygdala helps regulate emotions, specifically fear [1]. The basal nuclei is involved in
the planning of movements. The thalamus works as the sensory relay center. All sensory
information, minus smell, is directed by the thalamus to other areas of the brain for processing.
The hypothalamus helps oversees homeostasis by regulating the endocrine system and pituitary
gland [14]. In addition, this structure is also involved in memory and emotion. The pituitary
gland produces hormones related to growth and development as well as those linked to the renal
and reproductive systems [12].

Figure 1.3: The cerebral cortex broken down by each of the four lobes [3]
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There are two basic cell types found within the brain: neurons and glial cells [12].
Neurons communicate information and encompass the gray matter within the brain. Glial cells,
forming the white matter, are considered supportive cells and aid neurons in their function [13].
There are four types of glial cells found within the central nervous system (Figure 1.4). The most
abundant are the astrocytes. They perform a multitude of functions including balancing water
and ion concentrations as well as contributing to the blood-brain-barrier [3]. Oligodendrocytes
produce the phospholipid myelin that encapsulates and insulates neurons [14]. Microglia act as
phagocytic cells within the brain and move cellular debris and pathogens [15]. Ependymal cells
line the brain’s ventricles and produce cerebrospinal fluid (CSF) [12].

Figure 1.4: The four main types of glial cells [3]
1.2 Traumatic Brain Injuries:
Traumatic brain injuries (TBIs) are a type of acquired head trauma that occurs as a result
of an external force to the head that causes a varying level of neurological dysfunction [16].
Worldwide, TBIs are a leading cause of mortality and morbidity in individuals under 45 years
old [17]. While mild injuries will heal with no medical intervention, severe TBIs can cause
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significant behavioral changes and cognitive deficits [18]. The three main causes of a TBI are
falls, motor vehicle accidents, and being stuck or striking an object [19]. Severity can be further
categorized by type of traumatic brain injuries. The three main types include closed head,
penetrating, and explosive blast injuries [20]. Closed head injuries carry the highest incidence
rate of the three types. Penetrating injuries are less prevalent but far more severe as brain tissue is
exposed to the outside environment. Lastly, explosive blast injuries are traditionally only seen in
war zones, and are considered the most traumatic and complex. This injury is like a penetrating
injury but has an added complication resulting from the explosion’s shock waves pressures [21].
1.3 Penetrating Brain Injuries
Penetrating brain injuries (PBIs) occur when a foreign object enters the cranial cavity,
creating an opened wound. PBIs often result from high-velocity projectiles, such as firearms, and
are mostly seen in suicide attempts or on the battlefield [22]. The increased pressure from the
projectile causes cell necrosis along the pathway, ultimately creating a permanent crater or cavity
[4]. According to the Department of Defense, from 2000 to August 2021, out of 444,328
traumatic brain injuries reported in American service members, 5,562 were classifiable as a
penetrating brain injury [23].
Multiple variables, such as age, proximity to the weapon, ballistic properties of the
projectile, as well as the location and depth of penetration into the brain ,will determine the
severity of the primary injury [24]. Overall, the prognosis of penetrating brain injuries is often
grave. Most patients do not arrive at an emergency medical center before expiring. As of 2015,
66-90% of patients who experienced this type of injury died prior to arriving at a medical center
and only 51% of those that were admitted for treatment survive [25]. The wound resulting from a
penetrating mechanism can fall into five classifications: penetrating, perforating, tangential,
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ricochet, and careening (Figure 1.5). Classification of the subtype of PBI allows for more
effective clinical planning and treatment. Tangential injuries occur when there is no true
penetration of brain tissue, resulting in a superficial wound. This subtype carries the best
prognosis for patients. The most devastating subtype is a perforating injury. This wound
typically results from a close-range bullet or high-velocity projectile [26]. The staple of a
perforating injury is the distal exit of the projectile from the point of entry into the cranial cavity
[27].

Figure 1.5: Main subtypes of penetrating brain injury [4]
Currently, the standard of care at initial point of contact involves aggressive resuscitation
measures [25]. Airway management, protection of the spine, and blood pressure control are the
three main points of management prior to arriving at a trauma center [4]. Once in a hospital
setting, imaging, surgical debridement, and continued aggressive resuscitation are performed to
stabilize the patient [22]. Typically, a craniectomy or craniotomy is performed to reduce
intracranial pressure. Long-term hospitalization in an intensive care setting is normally required
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following emergency treatment. Prophylactic anticonvulsants and antibiotics are typically given
to the patient for at least one to two weeks after injury [28].
1.4 Primary vs. Secondary Injury
The pathophysiology of TBIs is explained through the two injuries that occur: primary
and secondary (Figure 1.6).The initial damage to the tissue from the blunt or penetrating force is
considered the primary injury [29]. Direct, rotational, and shear forces influence the tissue
damage and severity of the primary injury [30]. The primary injury involves tissue changes as a
result of the physical damage and can be classified as focal or diffuse. Focal injuries are
produced when the forces acting on the skull create localized damage to the tissue directly
underneath or adjacent to the point of impact [29]. Intracranial pathologies resulting from a focal
injury include epidural hematoma, subdural hematoma, subarachnoid hemorrhage, and
intraventricular hemorrhage. Epidural hematomas occur when there is bleeding outside of the
dura, while subdural hematomas are seen when bleeding is present inside of the dura.
Subarachnoid hemorrhages are typically caused by a ruptured aneurysm when blood collects
within the subarachnoid space. An intraventricular hemorrhage is when the bleeding moves into
the ventricles. Diffuse injuries are seen when there is broad damage to axons and vascular
structures beyond the point of impact [29]. Focal injuries can progress into diffuse injuries [18].
Diffuse axonal injuries are caused by rotational forces disturbing the white matter of the brain by
disrupting axons [18]. The location of shearing greatly impacts the severity of this injury, with a
portion of patients never regaining consciousness [31]. For those that survive the primary injury,
many will go on to suffer from increased neurological dysfunction. This development is due to
the secondary, or delayed, injury that occurs minutes to years after the primary injury. Secondary
injury occurs at the molecular level and impacts cellular processes [18]. This injury is comprised
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of edema, inflammation, mitochondrial dysfunction, and excitotoxicity [17]. While the primary
injury of a TBI can only be prevented, due to the evolvement with time, it may be possible to
prevent or mitigate secondary injury through effective and timely therapeutic intervention [31].

Figure 1.6: Primary versus secondary injury [5]
1.5 Edema:
Edema is defined as swelling caused by fluid entrapment within a tissue. There are two
forms of cerebral edema: cytotoxic and vasogenic. Cytotoxic cerebral edema is the result of
increased intracellular water accumulation caused by a disturbance in cellular homeostasis
caused by excitotoxicity and mitochondrial dysfunction [17]. Vasogenic cerebral edema is
described as extracellular water accumulation stemming from the disruption in the blood-brain
barrier (BBB) [17, 32]. As the volume of the brain increases, and the skull remains rigid in
comparison, the intracranial pressure (ICP) increases, which heighten the risk of cerebral
ischemia and intracranial hypertension [33]. Current treatment measures include hypertonic
saline, Mannitol, and decompressive craniectomy [34]. The intravenous (IV) administration of
hypertonic saline triggers the movement of fluid from intracellular to interstitial spaces, thus
reducing fluid found within the cranial space [35]. Mannitol, an IV injection, reduces the
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reabsorption of water and sodium in the renal system, thus reducing the overall water content
found within the body [33]. Lastly, a decompressive craniectomy is a surgical intervention that
removes a portion of the skull, which allows for the brain to swell freely without raising the
patient’s ICP [36].
1.6 Neuroinflammation:
Almost immediately following the primary injury, the body elicits a robust inflammatory
response within the brain as a protective mechanism. Initially, the BBB opens and glial cells,
microglia, and astrocytes all become activated [30]. Then, macrophages and leukocytes are
introduced to the injured tissue via the blood [37]. Next, cytokines and chemokines are released
and reach peak levels a few hours post-injury. These biomarkers involve proinflammatory
cytokines, such as interleukin 1 beta (IL-1β), interleukin 6 (IL-6), and tumor necrosis factor-α
(TNF-α), as well as anti-inflammatory cytokines, like transforming growth factor-β1 (TGF-β1)
and interleukin 10 (IL-10) [38]. It has been found that progressive and prolonged
neuroinflammation following a PBI is indicative of worsening neurodegeneration and overall
reduction of cognitive recovery post-injury [39]. Given that inflammation post-injury plays a
crucial role in the severity of the secondary injury, the use of anti-inflammatory therapeutics are
being investigated as an effective treatment for TBIs. Glucocorticoids are a class of steroid
hormones particularly used to reduce inflammation for a variety of disorders, such as Lupus and
asthma. Glucocorticoids work by downregulating the release of proinflammatory cytokines, thus
decreasing the inflammatory response created by the body [40]. The immunosuppressive nature
of glucocorticoids targets leukocytes to the reticuloendothelial system [41]. In patients suffering
from head trauma, it has been found that the systemic administration of glucocorticoids impacts
the plasticity of the hippocampus and prefrontal cortex, causing compromised memory and
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cognition [42]. In addition, this class of drug causes adrenal suppression, which is complicated
by the increased risk of secondary adrenal failure due to anatomical changes caused by TBIs
[43]. Methylprednisolone, a synthetic glucocorticoid, promotes apoptosis in the hypothalamus
and pituitary region when a high dose was administered post-injury, thus inducing critical
illness-related corticosteroid insufficiency (CIRC) [44].
1.7 Mitochondrial Dysfunction:
Cell death initiated by a TBI can be separated into two types: apoptosis and necrosis.
Necrosis is a direct result of the impact sustained to the brain. Apoptosis is programmed cell
death. Apoptosis can be either dependent or independent of Caspase, a large family of proteases
(Figure 1.6). Caspase-independent apoptosis is activated by a protein from the Bcl-2 family,
which triggers the release of apoptosis inducing factor (AIF) from the mitochondria [45]. The
NADH oxidase activity of AIF results in DNA fragmentation thus causing cell death [16].
Caspase-dependent apoptosis includes two pathways: intrinsic and extrinsic (Figure 1.7).
Apoptosis via the extrinsic pathway involves cell surface receptors. When TNF-1 (tumor
necrosis factor 1) or the Fas Ligand (FasL) bind to their respective receptors, death domain
proteins, such as the Fas associated death domain (FADD), are recruited [46]. The connection of
Fas with FADD creates the death-inducing signaling complex (DISC) [47]. The DISC then
activates the initiator proteins, caspase-8 and caspase-10. These specific caspases ultimately
activate caspase-3, which executes the apoptotic death [48]. The Caspase-dependent intrinsic
pathway is initiated by mitochondrial dysfunction [30]. The depolarization of the mitochondrial
membrane causes mitochondrial pores to be created causing the release of cytochrome c into the
cytoplasm [48]. This protein then forms an apoptosome with apoptotic protease activating factor1 (Apaf-1), which activates caspase-9, followed by caspase-3 [29].
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Figure 1.7: The caspase-dependent pathways of apoptosis [6]
1.8 Excitotoxicity:
Mitochondrial dysfunction is often caused by excitotoxicity, which is defined as cell
death that is the result of the excess release of excitatory neurotransmitters [49]. The most
abundant excitatory neurotransmitter found in the brain is glutamate and the typical cause of
excitotoxicity in TBIs. After the brain endures a blunt force, the extracellular concentration of
glutamate becomes significantly increased. Normally, glutamate is taken up by astrocytes
through an ATP-dependent transport system. With the amounts of available ATP and healthy
astrocytes diminished after a TBI, glutamate re-uptake is drastically reduced [29]. The
extracellular glutamate causes neurons and glial cells to undergo a large influx of Ca2+ and Na+
[50]. Once inside the cell, the mitochondria will take in Ca2+ to help regulate intracellular
concentrations. High Ca2+ concentrations within the mitochondria will cause the generation of
free radicals and reactive oxygen species (ROS), activation of nitric oxide synthase (NOS), and
formation of mitochondrial permeability transition pores (MPTPs) [49]. In addition,
mitochondrial production of a cell’s main energy source, adenosine triphosphate (ATP), through
oxidative phosphorylation is restricted [51]. All of these disturbances cause intracellular
accumulation of water molecules within neurons and glial cells, putting the patient at risk for
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cytotoxic cerebral edema [52]. Cyclosporin A (CsA), an immunosuppressive drug commonly
used following organ transplantation, has been used as a neuroprotective agent in TBIs [53]. CsA
works by inhibiting the opening of MPTPs, thus preventing the influx of Ca2+ ions into the
mitochondria [54].
1.9 Generation of Reactive Oxygen Species:
In homeostasis, the amount of free radicals, in the form of reactive oxygen species
(ROS), generated is balanced by antioxidant enzymes. Oxidative stress occurs when the amount
of ROS becomes overpowering, causing damage to cells, proteins, and DNA. This development
encourages apoptosis and necrosis, thus furthering edema and the breakdown of the BBB [55].
Free radicals are highly reactive as the result of their unpaired electrons. Within the electron
transport chain in the mitochondria, the free radical superoxide (O2-) is produced during the
reduction of oxygen via complex I and complex III. After a TBI, excitotoxicity and
mitochondrial dysfunction lead to an increased production of this free radical in the brain while
there is a significant drop in antioxidant production [56]. These oxygen radicals can cause lipid
peroxidation by removing a hydrogen atom from unsaturated fatty acids [37]. This event reduces
the integrity of membranes, causing cell death.
1.10 Infection Risk:
In addition to the complications seen in TBIs, PBIs have infection as an additional
concern. Infections are both an immediate and late complication of PBIs. Due to the introduction
of a non-sterile, foreign object into the cranial cavity, osteomyelitis, abscess, meningitis,
superficial tissue infections, and empyema can all form [22]. The most common bacteria seen in
these infections include Staphylococcus aureus and gram-negative bacteria [57]. To reduce the
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risk of infection, prophylactic broad spectrum antibiotics are given intravenously to these
patients and a surgical debridement of the wound is performed [58].
1.11 Current Research in Biomaterial-Based Drug Delivery for TBI and Related
Neurotrauma
The development of localized drug delivery systems utilizing hydrogels for the treatment
of various neurological injuries has become a significant interest for researchers. The primary
focuses include improving hemostasis for traumatic injuries, reducing neuroinflammation,
mitochondrial dysfunction, and oxidative stress associated with secondary injury, and promoting
neural regeneration. Hydrogels are biocompatible, biodegradable 3-D polymeric networks,
joined together via physical or chemical crosslinks, that are capable of retaining large volumes of
water without compromising their structural integrity [59]. These qualities make hydrogels a
potential candidate for the localized, sustained release of therapeutics, thus improving
bioavailability while minimizing systemic toxicity [60]. Hydrogel composition can include
naturally-derived polymers such as collagen, gelatin, cellulose, hyaluronic acid, and alginate, as
well as synthetic polymers like polyethylene glycol (PEG) and polyacrylamide (PAM) [61].
Altering the composition, matrix pore size, and crosslink density can allow for manipulation of
the drug release rates depending on the application.
The addition of growth and neurotrophic factors have been investigated for improving
angiogenesis and neurogenesis. The delivery of neurotrophins via poly(lactic-co-glycolicacid)
(PLGA) microparticles encapsulated in poly(ethylene glycol) (PEG)-based hydrogels was
studied for potential therapeutic benefit in neurodegenerative diseases [62]. The chosen
neurotrophins were brain-derived neurotrophic factor (BDNF) and glial-derived neurotrophic
factor (GDNF). It was concluded that the microparticles effectively released their respective NFs
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and reduced microglial activation, while increasing the number of proliferating cells and
migratory neuroblasts. Additionally, it was found that drug-loaded hydrogels composed of
HAMC allowed for a local release of erythropoietin (EPO) and improved neurogenesis after a
stroke [63]. The delivered EPO reduced apoptosis and increased the numbers of observed mature
neurons in treated mice following an induced stroke injury. It was also noted that the HAMC
reduced the inflammatory response as indicated by a lessened population of astrocytes and
activated microglia.
Hydrogels can be used for a localized delivery of pharmaceuticals. An example of this is
a localized hydrogel delivery system composed of HAMC used to deliver a sustained dose of
CsA for a potential treatment method of stroke patients [64]. As discussed earlier, CsA increases
the ability of mitochondria to buffer calcium ions, thus decreasing mitochondrial dysfunction.
Fabricated CsA-loaded hydrogel microparticles were injected directly onto the cortical surface
and were found to reduce the cerebral infarct volume after a stroke in rats. Another study
analyzed the use of hydrogels made of poly(N-isopropylacrylamide) loaded with magnolol
nanocrystals for normalization of ATP production [65]. Magnolol is a bioactive compound found
in magnolia bark that is utilized to treat Parkinson’s Disease. Results showed that these
hydrogels reduced mitochondrial dysfunction of the midbrain, improving ATP production and
reducing ROS generation. Another study developed an injectable hydrogel to reduce ROS
generation following a TBI [66]. The hydrogel was composed of triglycerol monostearate (TM)
and (propylene sulfide)120 (PPS120) with curcumin embedded. Curcumin is the active compound
found in turmeric and acts as a scavenger of ROS. The injectable hydrogel effectively reduced
ROS levels in astrocytes as well as decreased inflammation and neuronal regeneration in treated
mice following a TBI.
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2. RATIONALE & RESEARCH OBJECTIVE
2.1 Previous Work
This research study builds on a platform on hydrogel biomaterials developed for tissue
engineering and drug delivery in the research labs of Dr. Ken Webb and Dr. Jeoung Soo Lee at
Clemson University.
Kutty et. al. first investigated the ability of incorporation of native ECM components
within photocrosslinked poly (ethylene) glycol diacrylate (PEGdA) hydrogels to form semiinterpenetrating networks (semi-IPNs) that supported improved cell proliferation, migration, and
remodeling [67]. The three ECM components selected and investigated were collagen, gelatin,
and hyaluronic acid (HA). Despite being hydrolytically degradable, the poly (ethylene) glycolbis-(acryloyloxy acetate) (PEG-bis-AA) gel alone did not support cell proliferation or spreading.
It was found that the collagen and gelatin-based semi-IPNs had the same restricted cellular
morphology as PEG-bis-AA alone and offered no improvement to cell spreading, while the HA
did. The degradation of the HA hydrogel likely increased mesh size, which allowed the cell to
effectively spread. When hyaluronidase (HAse) inhibitors were added, fibroblast spreading was
not observed. Therefore, the critical mechanism involved was cell-mediated, enzymatic
degradation of the HA using HAse enzymes. Therefore, the addition of HA into semi-IPNs
provides an accelerated rate of cellular remodeling. Lee et. al. continued these studies and
demonstrated polymerization-induced phase separation, which they proposed created HAenriched domains that facilitated cell spreading within PEGdA/HA semi-IPNs [7]. As expected,
when native HA was replaced with a methacrylated HA derivative (GMHA), phase separation
was limited and cell spreading was eliminated.
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Based on Kutty’s work, it was hypothesized that HA could be used as a macromolecular
prodrug for localized delivery of bioactive small molecules. Specifically, covalent conjugation of
drugs to HA offered a means for their sequestration within the hydrogel network and subsequent
release in response to cell-mediated enzymatic remodeling. Bae et. al. created semi-IPNs
consisting of dexamethasone-conjugated hyaluronic acid (HA-DXM) and PEG-bis-(2acryloyloxy propanoate) to induce osteogenic differentiation [68] (Figure 2.1). Initially,
enzymatic release of DX was investigated. HA-DXM and PEG-bis-AP/HA-DXM semi-IPNs
were incubated in two conditions: 0.1M PBS, 0.1M PBS with esterase (Ease), and 0.1M PBS
with Hase and Ease. It was seen that the release of DX was much higher in the presence of these
enzymes. In order to investigate cell-mediated drug release, semi-IPNs consisting of HA-DXM
with and without human mesenchymal stem cells were incubated. In the presence of cells, DX
was released in a sustained manner for up to 20 days. Finally, HA-DXM containing semi-IPNs
were able to support osteogenic differentiation of encapsulated human mesenchymal stem cells.
This study proved that bioactive small molecules can be conjugated to HA and subsequently
released in response to cell-mediated enzymatic degradation for local, sustained delivery.

Figure 2.1: Photo-crosslinked semi-IPN hydrogels composed of PEG-bis-(2-acryloyloxy
propanoate) and dexamethasone-conjugated hyaluronic acid conjugates [68]
24

Jeong et. al. created a semi-IPN hydrogel consisting of HA-DXM and PEG-bis-AA for
localized drug delivery in order to investigate the ability of locally-delivered dexamethasone to
act as an anti-inflammatory drug to mitigate second injury and neuroinflammation following a
TBI [69]. As previously discussed, neuroinflammation is thought to be one of the most
significant causes of neuronal cell death. After rats sustained a controlled cortical impact,
hydrogel-discs were then placed on the cortex. The rats treated with hydrogel-discs incorporating
HA-DXM had reduced secondary injury including reduced proinflammatory cytokine mRNA,
reduced apoptosis and increased neuronal survival, as well as reduced lesion volume. Most
importantly, their motor function was significantly improved when compared to control groups
when performing behavioral tests such as a beam walk test. The time it took the rats treated with
the PEG-bis-AA/HA-DXM group to walk the beam was significantly reduced when compared to
the PEG-bis-AA/HA, but not significantly different from the sham group.
2.2 Current Objective & Rationale
The need for an injectable form arises due to the fact PBIs often create an unpredictable
and irregular-shaped wound that a pre-formed hydrogel would not appropriately fit. During
undergraduate honors research, initial attempts were made at investigating a crosslinking method
that could be applied to form hydrogel microparticles in an oil/water emulsion system. While
previous work relied on photoinitiated crosslinking, it was hypothesized that the ultraviolet (UV)
light requirement would provide challenges in an emulsion setting. Therefore, both
photoinitiation and an alternative method of oxidation-reduction (redox) were investigated for
radical polymerization. The studies showed that the method using redox chemistry was
unsatisfactory in terms of the degree of crosslinking achieved (Figure 2.2). The redox method,
using ammonium persulfate (APS) and tetramethylethylenediamine (TEMED), provided a mass
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swelling ratio of 1785% with a standard deviation of 42.35%. Additionally, the oxygen-sensitive
redox method was performed under Argon-purged environment, but this only saw slight
improvement with an average mass swelling ratio of 1574% and standard deviation of 70.07%.
Lastly, the photoinitiated group, formulated with 0.1% w/v I-2959, had a mass swelling ratio of
650% with a standard deviation of 28.78%. At this time, the photoinitiated method proved to be
more effective, thus microparticle fabrication in an emulsion ensued. While microparticle
fabrication was able to be achieved using the method described above, there were concerns
relating to insufficient yield size as hypothesized. The size of the water-in-oil emulsion used for
microparticle fabrication was constrained by the need for the UV light to penetrate throughout
the solution to effectively crosslink the microparticles.

Figure 2.2: Mass swelling ratio of PEGdA/HA semi-IPNs crosslinked by redox and
photo-initiated radical polymerization
The objective of this thesis was to develop a new hydrogel formulation utilizing Michaeltype addition as a crosslinking method compatible with emulsion-based microgel fabrication.
Michael-type addition reactions involve the addition of carbanion, or other nucleophile, to a α,β-
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unsaturated carbonyl compound that has an electron-withdrawing group. Michael-type addition
reactions between thiols and vinyl sulfones / maleimides results in stable bonds, while thiolacrylate conjugates include hydrolytically degradable ester linkages, offering a flexible approach
for the formulation of hydrogels for controlled drug-release [70]. Importantly, this Michael-type
reaction is insensitive to oxygen and not reliant on an exogenous initiator such as UV light [71].
Therefore, the use of this chemistry to fabricate hydrogel microparticles was expected to
overcome the previously noted challenges related to scalability.
Michael-type addition is a step-growth reaction, requiring one of the reactants to have 3
or more reactive groups for crosslinking. Gelatin is a protein derived from the hydrolysis of
collagen. Per the FDA, gelatin is considered to be ‘generally regarded as safe’ (GRAS) and is
widely used in cosmetics and food products [72]. From a biomaterial standpoint, gelatin’s
biocompatibility along with its chemically modifiable structure makes it a good choice for the
formation of hydrogels for drug delivery and tissue engineering applications [73]. Therefore,
thiolated gelatin was selected as a macromolecular, multi-functional component for the hydrogel.
Polyethylene diacrylate (PEGdA) were chosen as the crosslinking partner based upon PEG’s
excellent biocompatibility in a wide range of applications, including CNS implants [74].
Rheological studies were conducted on gelatin-SH/PEGdA hydrogels to investigate the
effect of pH and temperature on gelatin kinetics in order to optimize reaction times. Additionally,
gelatin-SH/PEGdA hydrogels were crosslinked to form bulk samples in order to investigate the
effect of gelatin-SH and HA concentrations on crosslinking time, storage modulus, swelling, and
degradation. Finally, microparticle were fabricated and sizing was characterized via imaging.
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3. METHODS & MATERIALS
3.1 Materials
Gelatin (type A), polyethylene glycol (PEG, 4kDa), acryloyl chloride, dichloromethane,
and triethylamine (TEA) were purchased from Sigma-Aldrich (St. Louis, MO). Dichloromethane
was dried overnight with calcium hydride, filtered, and stored over molecular sieves. γThiobutyrolactone was purchased from Santa Cruz (Dallas, TX). Ellman's reagent (5,5-dithiobis-(2-nitrobenzoic acid) was acquired from Thermo Fisher (Rockford, IL). Research grade
sodium hyaluronate (700 KDa and 1.5 MDa) was obtained from Lifecore Biomedical (Chaska,
MN). All water was filtered through a Milli-Q® Direct 8 water purification system and
dispensed at a resistivity of 18.2 MΩ.cm. The Labconco FreeZone freeze dryer was operated at a
temperature of -88℃ and pressure of 0.100 mBar for all the studies. All statical analysis was
performed using ANOVA.
3.2 Synthesis of Gelatin-SH:
Thiolated gelatin (gelatin-SH) was synthesized per US Patent 3,171,831 [75] as seen in
Figure 3.1 below. A 100 mL solution of 5% native gelatin in water was added to a 250 mL
Erlenmeyer flask and allowed to stir at 37 ℃ until homogeneously dissolved. 2.5 mL of TEA
was then added to increase the pH to a value between 10.5 and 11. Next, 300 mg of γthiobutyrolactone was added and the reaction was allowed to proceed for 90 minutes. The pH
was continuously monitored using a Denver Instrument UltraBasic pH Benchtop Meter (UB-10).
Small volumes of triethylamine were added to maintain the pH between 10.5 and 11. Once the
reaction was complete, 5N HCl was added to acidify the solution to a pH between 3 and 3.5. The
solution was then precipitated into 10X excess volume of ice cold (-20 ℃) acetone. The
acetone/water solution was decanted and 300 mL of fresh ice cold acetone was added to the
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beaker. Using a spatula, the gelatin-SH precipitate was manually crushed and fragmented. The
acetone/water solution was discarded again and fresh ice cold acetone added. This process was
repeated until a white powder remained that was recovered and dried under vacuum overnight.
The yield of the reaction varied between 95% to 97%.

Figure 3.1: Thiolation of native gelatin
To quantify the thiols present, an Ellman assay was performed per manufacturer’s
guidelines. The reaction buffer for the standards and sample was 0.1 M sodium phosphate
solution with a pH of 8.0. Samples of interest were dissolved at 0.5% and 0.1%. Utilizing
cysteine, standards of 250, 125, 62.5, 31.25, 15.625, 7.8125, 3.90625, and 0 μM were created. 4
mg of Ellman reagent per mL of reaction buffer was dissolved. 200 μL of each standard/sample
was added to a 96-well plate in triplicate fashion. 50 μL of the dissolved Ellman reagent was
added to each well. The plate was allowed to incubate at room temperature for 15 minutes then
absorbance was read at 412 nm in end-point fashion. A standard curve was created and the
sample’s thiol concentration was calculated. For all synthesized gelatin-SH, the average
micromoles per g of gelatin-SH was 172.5 with a standard deviation of 4.3.
3.3 Synthesis of PEGdA:
To begin, 120 mL of dried dichloromethane was added to a dry 250 ml flask while
purged with argon. Next, 15 g of PEG was introduced and allowed to completely dissolve while
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stirring. 0.939 mL of TEA was added and an ice bath placed underneath the flask, which was
allowed to cool for 10 minutes. 1.21 mL acryloyl chloride in 30 ml dichloromethane were placed
in an addition funnel and added dropwise to the PEG solution over the course of 30 minutes. The
reaction was allowed to run for 24 to 30 hours. The solution was then filtered using Cellite to
remove any salt formed and the solvent volume reduced to 10% by rotary evaporation. The
remaining solution was then precipitated in 10x diethyl ether and recovered by filtration. The
product was redissolved in dichloromethane (150 ml) and washed with 10% sodium bicarbonate
in water (15 mL) using a separatory funnel. After washing and separation, the organic phase was
recovered and its pH tested using pH paper. Washing was repeated (typically 3-4 times) until
neutral pH was achieved. The process was then repeated 3 additional times using deionized
water to remove any residual sodium bicarbonate. After final recovery, sodium sulphate was
added and stirred to remove excess water producing a clear solution. The product was then
vacuum filtered to remove any sodium sulphate particles, concentrated by rotary evaporation,
and precipitated in diethyl ether. The precipitate was crushed into a fine powder using a spatula
along the sides of the beaker then recovered by vacuum filtration. This process was performed
repeated twice. The powder was then gathered and placed under vacuum overnight. The
following day, the product was dissolved in deuterated chloroform and the structure of the
synthesized PEGdA was confirmed using a proton nuclear magnetic resonance (1H NMR)
spectrum (Bruker Avance 500 spectrometer).
3.4 Preparation of Hydrogel Precursor Solutions:
Stock precursor solutions of gelatin-SH, PEGdA, and HA were all created. HA was
dissolved at a 2% w/v in water overnight at room temperature. Immediately prior to
polymerization of hydrogels, gelatin-SH was dissolved at 10% w/v in water at 40 ℃. PEGdA
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was dissolved in water based on a 1:2 molar ratio of thiols to acrylates resulting in a 17% w/v
solution. The pH of the gelatin-SH and PEGdA solutions was measured with a Denver
Instrument UltraBasic pH Benchtop Meter (UB-10) and small additions of HCl and NaOH were
added to reach the desired pH. Any outstanding volume was resolved using water.
Group:
5% Gel-SH
5% Gel-SH/0.72%
HA (700K)
5% Gel-SH/0.36%
HA (1.5M)
3% Gel-SH
3% Gel-SH/0.72%
HA (700K)
3% Gel-SH/0.36%
HA (1.5M)

50

17%
PEGdA
(μL)
10

2% HA
(700K)
(μL)
-

2% HA
(1.5M)
(μL)
-

50

10

36

-

4

50

10

-

18

22

30

6

-

-

44

30

6

36

-

8

30

6

-

18

26

10 % GelSH (μL )

H2O/HCl/NaOH
(μL)
40

Table 3.1: Gelatin-SH/PEGdA hydrogel formulations
3.5 Preparation of Disc-Shaped Hydrogels:
Utilizing Figure 3.2, 10% gelatin-SH was added to a microcentrifuge tube. Immediately
after, the 17% PEG solution was added to the same tube for the Michael-type addition as seen in
Figure 3.3. The solution was vortexed until homogenous, spun down, then 100 μL was pipetted
between glass slides separated by 1 mm Teflon spacers. Each hydrogel was allowed to
polymerize for 60 minutes prior to collection at the specified temperature.
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Figure 3.2: Michael-type addition of gelatin-SH and PEGdA
3.6 Rheological Studies:
Rheological studies were performed using an Anton Paar rheometer (MCR 302e)
equipped with a parrel plate with a diameter of 10 mm. The normal force was initially applied at
0 N, with the frequency set at 0.1 Hz and an applied shear strain of 1%. The gap was closed at 1
mm. Using the formulations for the disc-shaped hydrogels in Figure 3.3, a total volume of 1 mL
per run was created. The solution was vortexed until homogenous, spun down, then 750 μL was
pipetted onto the plate of the rheometer. Once the parallel plate was lowered into the desired gap
position, excess material was scrapped away. Initially, a pH study was performed. Utilizing 5%
gelatin-SH, samples were created at 3 different pH values: 6.75, 7.0, and 7.25. These samples
were run at n=4 per group until crosslinking was achieved (approximately 10-30 minutes
depending on the group). Once the optimal pH was determined, runs using the 5% gelatin-SH
were performed at 37 ℃ and 22 ℃ (RT) for n=4 to analysis the effect of temperature on
crosslinking time. Lastly, all 6 groups noted in Figure 3.2 were run for an hour at RT for n=3 in
order to study the effect of gelatin-SH and HA on storage modulus.
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3.7 Effect of Gelatin-SH Concentration and the Incorporation of HA on Swelling:
The effect of the presence of HA and varying gelatin concentrations on crosslinking was
studied via a swelling study. After polymerization, the hydrogels were collected and each group
was incubated overnight in a 50 mL centrifuge tube containing 40 mL of PBS w/out at 37℃. The
following day, wet weights (WW) were obtained and each gel was placed into an individual 2
mL microcentrifuge tube and moved into a -80 ℃ freezer overnight. Next, all hydrogels were
then loaded onto a Labconco FreeZone freeze dryer overnight. Lasty, the dry weights (WD) were
obtained and the mass swelling ratio for each gel was calculated using the formula below.
Mass Swelling Ratio = Ww / WD
3.8 Effect of Gelatin-SH Concentration and the Incorporation of HA on Degradation:
Directly following polymerization, each gel was placed into a 5mL transport tube and
placed into a -80 ℃ freezer overnight. The gels were then loaded onto a Labconco FreeZone
freeze dryer overnight. The following day, the dry weights (W0) were obtained and 2 mL of 1x
PBS w/out, pH 7.4 was added to each tube. All tubes were placed on a low-speed shaker in a
warmed room (kept at approximately 35.5 °C). For days 6, 12, and 18, 4 samples per group were
collected, washed with Millipore water, frozen overnight at -80 ℃, then placed back on the
Labconco FreeZone freeze dryer overnight. Dry weights (WD) were then obtained and percent
mass loss was calculated using the equation below and compared across all time points.
Percent Mass Loss = (W0 – WD)/W0 * 100
3.9 Fabrication of Hydrogel Microparticles:
Hydrogel microparticles were synthesized in a water-in-oil emulsion. Using a 20 mL
scintillation vial, 9 mL of 2% w/v liquid lecithin in corn oil was added along with the stir bar.
After being set at the desired revolutions per minute (RPM), the solution was allowed to
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stabilize. Using the previously described stock solution, 900 μL of the gelatin-SH solution and
100 μL of the PEGdA stock were vortexed until homogenous, then spun down. Finally, 1000 μL
of the gelatin-SH/PEGdA solution was pipetted at the apex of the oil. Polymerization of each
sample was allowed 60 minutes for completion.
To remove oil and recover the newly fabricated microparticles, acetone was added to the
Scintillation vial until full and then shaken. After settling, the acetone-oil supernatant was
removed and more acetone was introduced to the vial, followed by shaking. This process was
completed 4 times. On the final wash, 10 mL of acetone was added and the solution was pipetted
into a 15 mL centrifuge tube. The tube was then vortexed, allowed to settle, and the acetone was
removed then replenished. This process was completed 3 times with acetone, with 5 mL of water
being added at the final wash instead of acetone.
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5. RESULTS & DISCUSSION
5.1 Gelatin-SH and PEGdA Synthesis
For the fabrication of hydrogel microparticles, gelatin was selected due to its
biocompatibility and biodegradability. In addition, gelatin has a chemically modifiable structure
that allows for the addition of functional groups, such as thiols. Covalent crosslinking via a
Michael-type addition reaction between the gelatin-SH and PEGdA was used to stabilize the
hydrogel structure.
The success of the PEGdA synthesis was analyzed using nuclear magnetic resonance
(NMR) as seen in figure 2.1. The efficiency of acrylation was calculated to be 80.3% based upon
the ratio of the peak integrals of terminal acrylate groups and the PEG backbone methylene
groups. During the synthesis of gelatin-SH, purification challenges were encountered. Initially,
the product was to be purified via performing a precipitation in acetone followed by vacuum
filtration three times. It was discovered that during the second and third precipitation, the gelatinSH quickly became more difficult to precipitate. When redissolving these gelatin-SH products, it
often took hours and created inconsistent solutions. Therefore, modifications to the washing
procedure denoted in US Patent 3,171,831 were made. The use of ice-cold acetone allowed for a
more crystalline precipitate, that could then be broken down via mechanical manipulation into a
fine white powder, which was easily dissolvable when creating hydrogel precursor solutions. The
alteration in purification methods increased the average thiol micromoles per g of gelatin-SH
from 138 to 172.5, which may be explained by the spontaneous formation of disulfide bonds
during prolonged heating for re-dissolution between precipitations. In order studies, the
thiolation of native gelatin with Traut’s reagent produced an average of 60.1 thiol micromoles
per g of gelatin-SH with a standard deviation of 22.1 [76].
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Figure 4.1: NMR of the PEGdA product. 10 mg of PEGdA was dissolved in 1 mL of deuterated
chloroform before having the structure analyzed via a 1H NMR spectrum.
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y5.2 Gelatin Kinetics & Mechanics
The first studies investigated gelation kinetics as a function of pH using 5% gelatin-SH
utilizing rheology. In figure 4.2, it is observed that increasing crosslink time occurs as pH
decreases, which was expected since Michael-type addition reactions are base-catalyzed. A
fourth pH of 6.50 was tested but no measurable crosslinking took place after 60 minutes. Since
the crosslinking time for this group was likely well over an hour long, it would not be an
applicable pH for this project so further studies were not performed. When accounting for
handling time, it was decided that the pH 7 offered the optimal crosslinking time with an average
of 4.83 minutes with a standard deviation of 1.03. This amount of time was a good choice as it
was sufficient for injecting the solution into the oil setting, while still allowing for stabilization
of the emulsion prior to rapid crosslinking.

Figure 4.2: The effect of pH on crosslinking time. Each condition was performed for n=4. Per
run, 750 μL of solution was studied at 37 ℃ utilizing a parallel plate on an Anton Paar rheometer
with a gap of 1 mm. The time of crosslinking was determined as the time point at which the
storage modulus exceeded the loss modulus.
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The second rheological studies investigated gelation kinetics as a function of temperature
using 5% gelatin-SH. In figure 4.3, it can be seen that the hydrogels polymerized at room
temperature exhibited a much shorter crosslinking time of 1 minute with a standard deviation of
0.33, while the studies performed at 37 °C took an average of 4.83 minutes with a standard
deviation of 1.04 to crosslink. When polymerized at room temperature, thermally induced, noncovalent crosslinking likely occurred prior to covalent crosslinking, which accounts for the
reduced crosslinking time observed. For simplicity, it was decided that microparticle fabrication
in an emulsion setting would be performed at room temperature.

Figure 4.3: The effect of polymerization temperature on crosslinking time. Each condition was
investigated at n=4. Per run, 750 μL of solution was studied at a specified temperature utilizing a
parallel plate on an Anton Paar rheometer with a gap of 1 mm. The time of crosslinking was
determined as the time point at which the storage modulus exceeded the loss modulus.
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Next, rheological studies were performed on varying formulations consisting of gelatinSH at two different concentrations (3% and 5%) and the addition of HA at two different
molecular weights and concentrations (0.72% 700K, 0.36% 1.5M) in order to investigate their
effects on gelation kinetics and mechanics. All runs were performed at 22 ℃ for 60 minutes
using parallel plates with a 1 mm gap at 0.1 Hz and 1% strain. This amount of time was selected
in order to capture the initial plateau of the storage modulus. In addition, it is a practical duration
for microparticle fabrication in an emulsion. Crosslinking time and final storage modulus are
shown in figures 4.4 and 4.5, respectively. Rheological data for each group is included in figures
4.6 to 4.11. In figure 4.4, it is seen that the 3% gelatin-SH with 0.72% HA (700K) had a
crosslinking time that was significantly different from the 3% gelatin-SH control. The average
crosslink time for the 3% gelatin-SH with 0.72% HA (700K) was 18.63 minutes with a large
standard deviation of 13.92. While the crosslinking time was not statistically different for the 3%
and 5% gelatin-SH groups with 0.36% HA (1.5M) in respect to their controls, there was a trend
of increasing gelatin-SH concentration and decreasing crosslink time. Alterations to the gelatinSH concentration did not significantly influence the crosslink time except for the groups
consisting of 0.72% HA (700K). This statistic and the large standard deviations observed in this
group was likely due to inhomogeneity caused by the increased amount of HA incorporated into
the solution, disrupting the interaction of gelatin-SH and PEGdA. This concern may have been
further exacerbated by decreased gelatin-SH concentrations. A possible confounding variable
could be that the precursor solutions were often left stirring at 40 ℃ for several hours when
running consecutive rheological studies, which could have led to the formation of disulfide
bonds between thiols. This premature crosslinking could increase the homogeneity of the gelatin-
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SH/PEGdA solutions, thus causing Michael-type addition crosslinking and the storage modulus
to be less consistent throughout runs.

* significantly different from same gelatin-SH concentration without HA (p<0.05)
# significantly different from opposing gelatin-SH concentration with same HA formulation (p<0.05)

Figure 4.4: The effect of gelatin-SH concentration and the incorporation of HA on crosslinking
time (n=3 samples / group). Rheological testing was performed at 22 °C using parallel plates
with a 1 mm gap at 0.1 Hz and 1% strain. The time of crosslinking was considered the point at
which the storage modulus exceeded the loss modulus. Statistical analysis was performed using
ANOVA.
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In addition to crosslinking time, the effect of varying concentrations of both gelatin-SH
and two different MW HA additives on the hydrogel mechanical properties was examined.
Increased storage modulus is an indirect measurement of the crosslinking efficiency of a
material. In figure 4.5, it is observed that the addition of HA (700K) to the 5% gelatin-SH
material significantly increased its storage modulus in comparison to the control group. When
reviewing the statistical analysis of the 3% gelatin-SH and 5% gelatin-SH, there was no
significant difference caused by gelatin-SH concentration. Additionally, the 3% and 5% gelatinSH groups incorporating 0.36% HA (1.5M) were not statistically different from their respective
controls without HA. While not statistically significant in the control groups, there is an observed
trend of increasing storage modulus with increasing gelatin-SH concentration when HA is
incorporated. The 5% gelatin-SH groups incorporating both MW HA (700K and 1.5M) were
significantly different from their respective 3% gelatin-SH groups with the same HA
formulation. This trend alludes to the increased crosslinking efficiency caused by the greater
number of functional groups available for the Michael-type addition.
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* significantly different from same gelatin-SH concentration without HA (p<0.05)
# significantly different from opposing gelatin-SH concentration with same HA formulation (p<0.05)

Figure 4.5: The effect of gelatin-SH concentration and the incorporation of HA on storage
modulus. Each group was investigated at n=3. Rheological testing was performed at 22 °C using
parallel plates with a 1 mm gap at 0.1 Hz and 1% strain. The value for the storage modulus was
considered the highest storage modulus reached by the sample during the run. Statistical analysis
was performed using ANOVA.
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Figure 4.6: Rheological analysis of 5% gelatin-SH without HA. The solution was analyzed for
n=3. Per run, 750 μL of solution was studied at 22 °C using parallel plates with a 1 mm gap at
0.1 Hz and 1% strain.
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Figure 4.7: Rheological analysis of 5% gelatin-SH with 0.72% HA (700K). The solution was
analyzed for n=3. Per run, 750 μL of solution was studied at 22 °C using parallel plates with a 1
mm gap at 0.1 Hz and 1% strain.
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Figure 4.8 Rheological analysis of 5% gelatin-SH with 0.36% HA (1.5M). The solution was
analyzed for n=3. Per run, 750 μL of solution was studied at 22 °C using parallel plates with a 1
mm gap at 0.1 Hz and 1% strain.
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Figure 4.9: Rheological analysis of 3% gelatin-SH without HA. The solution was analyzed for
n=3. Per run, 750 μL of solution was studied at 22 °C using parallel plates with a 1 mm gap at
0.1 Hz and 1% strain.
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Figure 4.10: Rheological analysis of 3% gelatin-SH with 0.72% HA (700K). The solution was
analyzed for n=3. Per run, 750 μL of solution was studied at 22 °C using parallel plates with a 1
mm gap at 0.1 Hz and 1% strain.
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Figure 4.11: Rheological analysis of 3% gelatin-SH with 0.36% HA (1.5M). The solution was
analyzed for n=3. Per run, 750 μL of solution was studied at 22 °C using parallel plates with a 1
mm gap at 0.1 Hz and 1% strain.
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5.3 Bulk Characterization – Swelling Study
Bulk characterization was performed to investigate the crosslinking efficiency in a
swelling study depicted in figure 4.12. It was found that the 5% gelatin-SH groups were
significantly more resistant to swelling than the 3% gelatin-SH groups when polymerized in both
conditions. With increasing gelatin-SH and PEGdA concentrations, there are more thiol and
acrylate groups available for polymerization, thus allowing for more efficient crosslinking within
the material. At both temperatures, the incorporation of HA had did not have a significant effect
on hydrogel swelling except for the 5% gelatin-SH with 0.72% HA (700K), which was
significantly higher than the 5% gelatin-SH control. The increased HA concentration may have
caused disruption in the ability for gelatin-SH and PEGdA to effectively crosslink. This study
confirmed the use of a room temperature setting for microparticle fabrication as it is clear that
thermal gelation facilitates the improved efficiency of covalent crosslinking.
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* significantly different from same gelatin-SH concentration without HA at same temperature (p<0.05)
# significantly different from opposing gelatin-SH concentration with same HA formulation at same temperature (p<0.05)
% significantly different from same gelatin-SH/HA formulation at opposing temperature condition (p<0.05)

Figure 4.12: The effect of gelatin-SH concentration, incorporation of HA, and polymerization
temperature on mass swelling ratio. 100 μL hydrogels were polymerized at a specified
temperature between glass slides separated by 1mm Teflon spacers. All hydrogels were then
incubated in PBS w/out at 37℃ overnight. Wet weights (WW) were obtained. The hydrogels
were then frozen and lyophilized overnight. Dry weights (WD) were obtained and the mass
swelling ratio for each gel was calculated as Ww / WD. Statistical analysis was performed using
ANOVA.

50

5.4 Bulk Characterization – Degradation Study
Lastly, because the Michael-type addition between thiols and acrylates leave ester bonds,
the hydrolytic degradation of bulk hydrogel samples was investigated. No statistically significant
difference was found between the 6 conditions. Therefore, it can be said that variations in
gelatin-SH concentration and the incorporation of HA had no significant influence on
degradation. As seen in figure 4.13 and 4.14, it is observed that the percent mass loss decreased
with increasing gelatin-SH concentration. At day 18, the 3% gelatin-SH without HA group had a
percent mass loss of 52.54% with a standard deviation of 3.03%, while the 5% gelatin-SH
without HA group had a value of 29.63% with a standard deviation of 8.40%. Degradation is
driven by more than just hydrolysis in an organism. For example, enzymatic degradation of this
material would be catalyzed by collagenase and HAse, which would affect the gelatin matrix and
HA respectively. Therefore, it is expected that degradation would occur more rapidly in an
animal model.
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Figure 4.13: Hydrolytic degradation of 3% gelatin-SH hydrogels and semi-IPNs containing HA.
100 μL hydrogels were polymerized at 22 °C between glass slides separated by 1mm Teflon
spacers. All hydrogels were then incubated in PBS w/out at 22 ℃ overnight. The hydrogels were
then frozen and placed on a freeze dryer overnight. Initial dry weights (W0) were obtained. The
hydrogels were then placed inside on a low-speed shaker inside of a warmed room (kept at
approximately 35.5 °C). At each time point, 4 gels were removed, washed with water, placed in a
freezer overnight, then loaded onto a freeze dryer. Dry weights (WD) were then obtained and
percent mass loss was calculated as (W0 – WD)/W0 * 100. Statistical analysis was performed
using ANOVA.
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Figure 4.14: Hydrolytic degradation of 5% gelatin-SH hydrogels and semi-IPNs containing HA.
100 μL hydrogels were polymerized at 22 °C between glass slides separated by 1mm Teflon
spacers. All hydrogels were then incubated in PBS w/out at 22 ℃ overnight. The hydrogels were
then frozen and placed on a freeze dryer overnight. Initial dry weights (W0) were obtained. The
hydrogels were then placed on a low-speed shaker in a warmed room (kept at approximately 35.5
°C). At each time point, 4 gels were removed, washed with water, placed in a freezer overnight,
then loaded onto a freeze dryer. Dry weights (WD) were then obtained and percent mass loss was
calculated as (W0 – WD)/W0 * 100. Statistical analysis was performed using ANOVA.
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5.5 Microparticle Fabrication & Characterization
Lastly, emulsion-based microparticle fabrication was successfully performed. In figure
4.15, the effect of gelatin concentration and the incorporation of different molecular weight HA
on average microparticle diameter was investigated at two different speeds (400 and 600 RPM).
The microparticles were visualized and measured using a light microscope and digital image
acquisition and analysis software (figure 4.16). When comparing to the control groups (gelatinSH hydrogels), the incorporation of HA had no significant effect on the average diameter.
Gelatin-SH concentration had no significant effect on the diameter both stir speeds except for the
groups containing 0.72% HA (700K). Despite there being no statistical difference, a trend
observed in figure 4.15 was that as RPM increased, the average diameter of the particles
decreased. The viscosity of the solution decreases as gelatin-SH concentration decreases,
therefore they are more easily incorporated into the emulsion setting. Both the absence of HA
and the reduction of gelatin-SH concentration appear to cause the viscosity of the solution to be
reduced. This quality allows for easier incorporation into the emulsion setting, thus creating
smaller microparticles.
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* significantly different from same gelatin-SH concentration without HA at same stir speed (p<0.05)
# significantly different from opposing gelatin-SH concentration with same HA formulation at same stir speed (p<0.05)
% significantly different from same gelatin-SH/HA formulation at opposing stir speed (p<0.05)

Figure 4.15: The effect of gelatin-SH concentration and the incorporation of HA on microparticle
diameter at different stir rates. Using a water-in-oil emulsion, 2% lecithin in corn oil and gelatinSH/PEGdA was added at a ratio of 1:9. Polymerization occurred at room temperature for 60
minutes. Acetone washes were used to remove the oil following completion of the reaction. The
microparticles were imaged using ProgRes CapturePro and calibrated diameter measurements
were obtained via iSolution software. Statistical analysis was performed using ANOVA.
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Figure 4.16: Images of 5% gelatin-SH microparticles fabricated at 400 RPM at 10x. From top to
bottom: without HA, with 0.72% HA (700K), and 0.36% HA (1.5M). To visualize the fabricated
microparticles, a small volume of each group was placed into a well of a 96-well plate and
viewed using a light microscope. The computer application ProgRes CapturePro captured
images, which were then uploaded into iSolution for calibrated measurements.
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6. CONCLUSIONS
This project found that hydrogel microparticles capable of conforming to the irregular
geometry of PBIs can be successfully fabricated in a scalable emulsion setting. Covalent
crosslinking was achieved through the Michael-type addition of gelatin-SH/PEGdA. In bulk
characterization studies, it was observed that increased gelatin-SH concentration provided the
material with increased crosslink efficiency, corresponding to increased mechanical properties
and slower hydrolytic degradation. Native HA was incorporated to model HA-based
macromolecular prodrugs. The incorporation of HA had little effect on the physical properties of
the hydrogels. Further optimization and development of gelatin-SH/PEGdA microparticles could
potentially allow for the localized delivery of biologics to a PBI.
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7. RECOMMENDATIONS
Following the completion of this thesis, recommendations for future work include:
-

Compression testing to further investigate the effect of gelatin-SH concentration and the
incorporation of HA on gelation mechanics

-

Incorporation of dexamethasone-conjugated hyaluronic acid (HA-DXM) into the
hydrogels

-

Drug release studies to analyze hydrolytic and enzymatic degradation

-

Animal studies to analyze the effects of the drug-loaded hydrogel microparticles on
inflammatory cytokines
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